Rigel Pharmaceuticals | RIGL - Заемный капитал





Заемный капитал Изменить Дата
Agenus USD 169.66M 146.06M 2025-12
Amgen USD 51.89B 1.88B 2026-03
Arrowhead Research USD 1.23B 687.3M 2026-03
AstraZeneca USD 25.96B 177M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Daiichi Sankyo JPY 300.15B 199.41B 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Halozyme Therapeutics USD 1.94B 206.73M 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Intrexon USD 0 198.67M 2024-06
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Ligand Pharmaceuticals USD 446.19M 702K 2025-12
MacroGenics USD 70M 256K 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Pfizer USD 60.57B 1.08B 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Rigel Pharmaceuticals USD 0 0 2024-09
Sangamo BioSciences USD 0 0 2022-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Veracyte USD 0 0 2025-03